Agree, there are some positives like the below:
Penetration continues to increase, with approximately 30% of the 5,000 diagnosed patients having initiated therapy. In market research, physicians surveyed stated that over the next 24 months they expect to expand prescribing to more than 70% of their eligible patients.
Once the FDA meeting is completed in September, and hopefully further indications announced the Board just needs to wrap a bow around the company.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$11.95 |
Change
-0.590(4.70%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.92 | $825.3K | 68.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 105 | $11.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.96 | 543 | 2 |
View Market Depth
| Last trade - 10.15am 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |